Our strategy at the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) is to take advantage of discoveries in basic cancer biology, in conjunction with clinical research to: (1) develop and apply innovative therapeutic and preventive strategies to cancer patients;(2) describe the molecular mechanisms involving specific clinical phenotypes and behaviors;and (3) apply discoveries and strategies to the Maryland community, with the specific focus on cancer disparities. In this application, UMGCC seeks its first competitive renewal of the successful Cancer Center Support Grant (CCSG) application that was awarded in August 2008, in the present application, UMGCC is represented by 215 members working in five full and one developing research programs with 10 full and 3 developing shared services. UMGCC provides an effective umbrella supporting the multidisciplinary cancer research activities of this talented group of investigators. Total cancer funding rose from $47.1 million in 2007 to $62.0 million in 2009. NCI funding in that time increased from $14.4 million to $25.7 million. Supplements will push total cancer funding above $80 million in 2010. In FY2009, UMGCC served almost 2,300 new cancer patients and handled 43,547 outpatient visits, 32,405 infusion visits, and 1,327 inpatient admissions. During FY2009, 1,198 patients participated in over 200 clinical trials. Remarkably, 33 percent of clinical trial participants in FY2009 were underrepresented minorities, reflecting UMGCC's unique position and mission to involve the minority community in state-of-the-art clinical/translational research. UMGCC researchers have made outstanding contributions to our understanding of cancer biology, and important recent work from our laboratories and clinics is now the standard of care worldwide. A 2010 nationwide ranking of U.S. cancer programs placed UMGCC 21st out of more than 900 cancer programs and 18th among NCI-designated centers. Reflecting our remarkable and continued growth, UMGCC seeks to renew its CCSG to enhance and expand its efforts in high-quality and clinically relevant cancer research.

Public Health Relevance

The mission of the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) is to undertake innovative basic and clinical research that will impact the understanding and treatment of cancer around the world and to provide state-of-the-art clinical care to cancer patients in Maryland and beyond.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA134274-05
Application #
8324184
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
2008-08-08
Project End
2016-07-31
Budget Start
2012-09-14
Budget End
2013-07-31
Support Year
5
Fiscal Year
2012
Total Cost
$1,565,163
Indirect Cost
$545,513
Name
University of Maryland Baltimore
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Nygård, Lotte; Vogelius, Ivan R; Fischer, Barbara M et al. (2016) Early lesion-specific (18)F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer. Radiother Oncol 118:460-4
Fox, Jennifer M; Moynihan, James R; Mott, Bryan T et al. (2016) Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs. Oncotarget 7:7268-79
Joseph, Ann Mary; Srivastava, Ratika; Zabaleta, Jovanny et al. (2016) Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects. Cancer Immunol Res 4:708-16
Zandberg, Dan P; Liu, Sandy; Goloubeva, Olga et al. (2016) Oropharyngeal cancer as a driver of racial outcome disparities in squamous cell carcinoma of the head and neck: 10-year experience at the University of Maryland Greenebaum Cancer Center. Head Neck 38:564-72
Doshi, Kshama A; Trotta, Rossana; Natarajan, Karthika et al. (2016) Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress. Oncotarget 7:48280-48295
Ambulos Jr, Nicholas P; Schumaker, Lisa M; Mathias, Trevor J et al. (2016) Next-Generation Sequencing-Based HPV Genotyping Assay Validated in Formalin-Fixed, Paraffin-Embedded Oropharyngeal and Cervical Cancer Specimens. J Biomol Tech 27:46-52
Temburnikar, Kartik W; Ross, Christina R; Wilson, Gerald M et al. (2015) Antiproliferative activities of halogenated pyrrolo[3,2-d]pyrimidines. Bioorg Med Chem 23:4354-63
Kochel, Tyler J; Fulton, Amy M (2015) Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer. Prostaglandins Other Lipid Mediat 116-117:99-103
Rasmussen, Jacob H; Vogelius, Ivan R; Aznar, Marianne C et al. (2015) Spatio-temporal stability of pre-treatment 18F-Fludeoxyglucose uptake in head and neck squamous cell carcinomas sufficient for dose painting. Acta Oncol 54:1416-22
Shih, Yu-Huan; Zhang, Yuji; Ding, Yonghe et al. (2015) Cardiac transcriptome and dilated cardiomyopathy genes in zebrafish. Circ Cardiovasc Genet 8:261-9

Showing the most recent 10 out of 207 publications